<?xml version="1.0" encoding="UTF-8"?>
<p id="para580">The results of this trial are consistent with previous findings from phase 3 trials of lenalidomide maintenance therapy. In transplantation-eligible patients, three studies have shown that the addition of lenalidomide maintenance after autologous stem-cell transplantation reduces the risk of progression or death by approximately 50% compared with placebo or no maintenance.
 <xref rid="bib7" ref-type="bibr">7</xref>, 
 <xref rid="bib8" ref-type="bibr">8</xref>, 
 <xref rid="bib9" ref-type="bibr">9</xref> A significant improvement in overall survival has only been observed in one previous trial,
 <xref rid="bib8" ref-type="bibr">
  <sup>8</sup>
 </xref> although a recent meta-analysis did suggest an overall survival improvement in patients treated with lenalidomide in this setting.
 <xref rid="bib15" ref-type="bibr">
  <sup>15</sup>
 </xref> To take account of all available results so far now including the Myeloma XI study, we did a summary data meta-analysis, which showed that lenalidomide maintenance therapy reduced the risk of death.
</p>
